<DOC>
	<DOCNO>NCT02735239</DOCNO>
	<brief_summary>This open-label , Phase 1/2 study evaluate safety durvalumab ( MEDI4736 ) combination oxaliplatin/capecitabine chemotherapy metastatic/locally advanced oesophageal cancer ( OC ) neoadjuvant chemo ( radio ) therapy surgery operable OC . The immunotherapy give 4-week period start standard chemo ( radio ) therapy , continue durvalumab treatment chemotherapy start . The study include 2 phase , safety run-in Phase 1 ( Cohorts A1 A2 ) expansion Phase 2 ( Cohorts B , C , D ) .</brief_summary>
	<brief_title>Study Anti-PD-L1 Combination With Chemo ( Radio ) Therapy Oesophageal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Histological diagnosis oesophageal gastrooesophageal cancer Cohorts A B metastatic/locally advance cancer Cohorts C D deem suitable surgery curative intent 2 . Recovered prior therapy ( Grade 1 persistent Adverse Events acceptable ) 3 . Anticipated lifespan great 4 month 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 5 . At time day 1 study , subject brain metastasis must asymptomatic least 4 week : least 8 week without tumour progression whole brain radiotherapy least 4 week since craniotomy resection stereotactic radiosurgery least 3 week without new brain metastasis evidence MRI/CT 6 . Adequate normal organ marrow function define . Laboratory parameter vital function normal range . Laboratory abnormality clinically significant generally permit , except follow laboratory parameter , must within range specify , regardless clinical significance : Hemoglobin ≥ 9 g/dL Neutrophil count ≥ 1.5 x 109/L Platelet count ≥ 100,000/mm3 Serum creatinine , Creatinine Clearance ≤ 1.5x Institutional Upper Limit Normal ( ULN ) , ≥ 40 mL/min ( CockcroftGault formula ) Aspartate Aminotransferase ( AST ) /Alanine Aminotransferase ( ALT ) Aspartate Aminotransferase ( AST ) ( SGOT ) /Alanine Aminotransferase ( ALT ) ( SGPT ) : ≤ 2.5 x institutional upper limit normal Alkaline phosphatase ≤ 2.5 x ULN Serum bilirubin ≤ 1.5 x institutional upper limit normal ( ULN ) . This apply subject confirm Gilbert 's syndrome ( persistent recurrent hyperbilirubinemia predominantly unconjugated absence hemolysis hepatic pathology ) , allow consultation physician . 7 . Written inform consent obtain subject prior performing protocolrelated procedure , include screen evaluation . 8 . Age 18 year . 9 . Have inform treatment option 10 . Willing able comply protocol duration study include undergoing treatment , schedule visit , examination , biopsy follow Exclusion Criteria 1 . Involvement plan and/or conduct study ( applies AstraZeneca staff and/or staff study site ) . Previous enrollment present study . 2 . Participation another clinical study investigational product last 6 week 3 . Prior concurrent systemic anticancer therapy ( chemotherapy , immunotherapy , endocrine therapy , target therapy , biologic therapy , tumour embolization , monoclonal antibody , investigational agent ) 4 . Mean QT interval correct heart rate ( QTc ) ≥470 m calculate 3 electrocardiogram ( ECGs ) use Fredericia 's Correction 5 . Current prior use immunosuppressive medication within 28 day first dose study drug , exception intranasal inhaled corticosteroid systemic corticosteroid physiological dos , exceed 10 mg/day prednisone , equivalent corticosteroid 6 . Active prior document autoimmune disease within past 2 year . Subjects vitiligo , Grave 's disease , psoriasis require systemic treatment ( within past 2 year ) exclude 7 . Active prior document inflammatory bowel disease ( e.g. , Crohn 's disease , ulcerative colitis ) 8 . History allogeneic organ transplant 9 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , uncontrolled hypertension , unstable angina pectoris , cardiac arrhythmia , active peptic ulcer disease gastritis , active bleeding diatheses include subject know evidence acute chronic hepatitis B , hepatitis C , know immunodeficiency human immunodeficiency virus ( HIV ) , psychiatric illness/social situation would limit compliance study requirement compromise ability subject give write informed consent 10 . Known history previous clinical diagnosis tuberculosis 11 . Receipt live attenuate vaccination within 30 day prior study entry within 30 day receive durvalumab 12 . Prior exposure tremelimumab / durvalumab checkpoint inhibitor , antiCytotoxic Tlymphocyteassociated protein 4 ( CTLA4 ) antiProgrammed cell death protein 1 ( PD1 ) /antiProgrammed death ligand 1 ( PDL1 ) antibody . 13 . History severe allergic reaction unknown allergen component study drug . 14 . Known dihydropyrimidine dehydrogenase ( DPD ) deficiency 15 . Treatment sorivudine chemically related analogue , brivudine 16 . Peripheral sensitive neuropathy functional impairment prior first course 17 . History sarcoidosis syndrome . 18 . Metastatic disease central nervous system therapeutic option , include radiotherapy , may available . 19 . History pneumonitis interstitial lung disease . 20 . Major surgical procedure ( defined investigator ) within 30 day prior Day 1 still recover prior surgery . 21 . Women breast feed pregnant evidence positive serum pregnancy test ( minimum sensitivity 25 IU/L equivalent unit Human Chorionic Gonadotropin ( HCG ) . 22 . Any condition , clinical judgment treat physician , likely would interfere evaluation study treatment , interpretation subject safety study result , prevent subject comply aspect protocol may put subject unacceptable risk . 23 . Subjects donate blood participate study least 90 day follow last infusion durvalumab time specify prescribe information oxaliplatin capecitabine , whichever long 24 . For oxaliplatin capecitabine , refer prescribe information additional information</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Oesophageal Cancer</keyword>
	<keyword>Oesophageal adenocarcinoma</keyword>
	<keyword>Oesophageal squamous cell carcinoma</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Cytotoxic T-lymphocyte-associated protein 4 ( CTLA-4 )</keyword>
	<keyword>Programmed cell death protein 1 ( PD-1 )</keyword>
	<keyword>Programmed death ligand 1 ( PD-L1 )</keyword>
</DOC>